Tag: Alliqua BioMedical

YARDLEY, Pa. - Wound care provider Alliqua BioMedical reported total revenue of $5.5 million for the second quarter of 2016, up 75% year-over-year, compared to revenue of $3.1 million for the same period last year. Income from operations was $2.1 million for the quarter this year, compared to a loss of $8.4 million for the quarter last year. Alliqua reported total revenue of $8.4 million for the first six months of 2016, up 108%, compared to revenue of $4 million for the same period last year. Net...

WASHINGTON - Results are in for the AAHomecare HME Audit Key survey for the first quarter of 2016. Sixty-nine percent of completed MAC prepayment audits nationwide were paid upon review, according to the survey, which included additional documentation requests from Oct. 1, 2015, through March 31, 2016. Other results from the survey: . the average rate of audits denied increased 5% between the fourth quarter of 2015 and the first quarter of 2016, with the average percent of audits denied...

YARDLEY, Pa., and CHARLOTTE, N.C. - Alliqua BioMedical, a provider of wound care products, has signed a definitive agreement with BSN Medical for the exclusive distribution rights for its Sorbion, Sachet and Sorbion Sana primary dressings in the U.S., Canada and Latin America. Per the agreement, BSN will pay Alliqua $4.4 million to purchase the rights of Alliqua's existing distribution agreement with Sorbion GmbH & Co KG, now owned by BSN Medical. “The sale of Alliqua's exclusive distribution...

YARDLEY, Pa. - Alliqua BioMedical, a provider of advanced wound care products, reported revenues of $4.6 million for the first quarter of 2016, an increase of 120% over the same period a year ago. Organic total growth was approximately 4%. Product revenue was $4.1 million for the quarter, a 177% increase over the same period in 2015. “We remain extremely encouraged by the compelling commercial opportunity for our portfolio of advanced wound care technologies and expect that our continued execution...

LANGHORNE, Pa. - Alliqua BioMedical, a provider of advanced wound care products, has raised $34.5 million through a public offering. The company, listed on the NASDAQ as ALOA, sold about 6.6 million shares of its common stock at a price of $4.55 per share. Alliqua plans to use the net proceeds from the offering to “fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes,” according...

LANGHORNE, Pa. - Alliqua Medical has announced a public offering of common stock. The provider of advanced wound care products has announced pricing of an underwritten public offering of 6.6 million of its common stock at a price to the public of $4.55 per share. It expects to close the offering on May 4. Alliqua will use net proceeds from the offering to fund the expansion of its marketed products, explore additional products platforms and increase working capital, according to a press release.

LANGHORNE, Pa. - Alliqua BioMedical, a maker of wound care products, has agreed to acquire Eden Prairie-based Celleration for $30.4 million in stock and cash, according to an article in the Philadelphia Business Journal. Celleration is the manufacturer of MIST Therapy, an ultrasound system for treating acute and chronic wounds. Celleration had revenues of about $8.7 million in 2014. The deal will nearly double the size of Alliqua's sales force, said CEO David Johnson in the article.

WASHINGTON - AAHomecare plans to build a system to track the Medicare audits that are devastating HME providers, the association announced during its Washington Legislative Conference last week. “Good data informs good decisions,” said Tom Ryan, president and CEO of the association, in a release. “We're ready to work on behalf of the industry to collect and quantify the impacts of audits and present compelling facts that policymakers cannot ignore.” AAHomecare worked with...

LANGHORNE, Pa. - Alliqua, a provider of advanced wound care products, has acquired Choice Therapeutics for $4 million in stock and cash. The agreement, effective May 5, provides for an additional contingency payment of up to $5 million in stock or cash if stated revenue thresholds are reached over the next three years ending April 30, 2017. Alliqua has acquired Choice's wound care portfolio, its technology platform, and its sales and marketing team. The portfolio includes a TheraBond Antimicrobial...

ATLANTA - Brightree has acquired McKinney, Texas-based MedAct, adding 330 HME providers to its customer base. “With the addition of MedAct, we are expanding our market reach to include some of the industry's most nimble HME providers,” said Dave Cormack, president and CEO of Brightree, in a release. MedAct's customers will join Brightree's more than 3,000 customers. Under the terms of the agreement, MedAct CEO Gregg Timmons joins Brightree as executive vice president,...